Search results
Transforming Ipsen for sustainable growth . Over the past three years, we have shifted from reliance on a single blockbuster to four growth platforms. In 2023, we further enriched our portfolio with the acquisition of Albireo, and since 2020, we’ve added more than 25 new programs to our pipeline.
Today, the manufacturing facility is the world’s largest producer of vacuum furnace hot zones. Ipsen introduces Global VR, a TurboTreater unit with convection, the AvaC furnace and the TITAN furnace, a compact, global platform vacuum furnace. International operations expand to India and Japan, and Ipsen Germany celebrates 50 years in business.
Ipsen also licensed cabozantinib from Exelixis, which received marketing authorization the same year for the second-line treatment of advanced renal cell carcinoma. In January the following year, Ipsen announced the acquisition of certain assets of Merrimack Pharmaceuticals, including Onivyde ® , for the treatment of pancreatic and ovarian cancer.
Ipsen пропонує захоплюючі можливості, які кинуть виклик вашим здібностям, розширять ваші навички та винагородять ваш внесок у позитивній атмосфері особистого та професійного розвитку.
To request medical information on Ipsen’s products, report an adverse event or report a complaint, please visit: www.ipsenmedicalinformation.com or email us at globalmedinfo@ipsen.com. Adverse event reactions can also be reported directly to Ipsen’s local safety team using the contact details provided in the list below.
Apr 24, 2024 · The agreement gives Ipsen exclusive worldwide rights to develop and commercialize STRO-003 and is the first ADC candidate to join Ipsen’s expanding pipeline. Ipsen and Skyhawk Therapeutics announced, in April 2024, the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare ...
Feb 13, 2024 · Ipsen itself believes the drug could eventually reach 500 million euros in peak sales by growing its share in both the front-line and post-chemo settings, a company spokesperson told Fierce Pharma.
